Longeveron (LGVN) – StreetInsider.com Reports
-
Longeveron (LGVN) Announces Exercise of Warrants for $6.2 Million Gross Proceeds
-
Longeveron (LGVN) Files for 145K Share Offering by Selling Stockholders
-
Longeveron (LGVN) CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at AAIC
-
Longeveron (LGVN) Announces Pricing of $5.25 Million Public Offering
-
Longeveron (LGVN) Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
-
Longeveron (LGVN) Files for Share and Warrant Offering
-
Longeveron (LGVN) Announces 1:10 Reverse Share Split
-
Longeveron (LGVN) Receives Nasdaq Non-compliance Notice
-
Longeveron (LGVN) Misses Q4 EPS by 81c
-
Longeveron (LGVN) Announces 1.45M Share Offering by Selling Stockholders
-
Longeveron (LGVN) Receives Notice of US Patent Allowance for Lomecel-B
-
Longeveron (LGVN) Announces 1.36M Share Offering at $1.62/sh
-
Longeveron (LGVN) Reports Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial
-
H.C. Wainwright Starts Longeveron (LGVN) at Buy
-
Longeveron (LGVN) Announces 5.02M Share Offering by Selling Stockholders
-
Longeveron (LGVN) Misses Q3 EPS by 5c
-
Longeveron (LGVN) Announces $4 Million Registered Direct Offering of Common Stock, Warrants
-
Longeveron (LGVN) Climbs 45% Following Positive Top-Line Results for Lomecel-B
-
Longeveron (LGVN) Reports Positive Top-Line Results for Lomecel-B
-
Longeveron (LGVN) Issues Letter to Stockholders
-
Longeveron (LGVN) Rights Offering Declared Effective and Calendar Finalized
-
Longeveron (LGVN) Misses Q2 EPS by 2c
-
Longeveron (LGVN) Acquires 50%+ Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B
-
Longeveron (LGVN) Appoints Lisa Locklear as CFO
-
Longeveron (LGVN) Appoints Dr. Nataliya Agafonova as Chief Medical Officer
-
Longeveron (LGVN) Files for Rights Offering
-
EF Hutton Assumes Longeveron (LGVN) at Buy
-
Longeveron (LGVN) Reports In-Line Q1 EPS
-
Longeveron (LGVN) Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome
-
Longeveron (LGVN) Misses Q4 EPS by 1c
-
Longeveron (LGVN) Appoints Wa’el Hashad as CEO
-
Longeveron (LGVN) Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
-
Longeveron (LGVN) granted European patent related to stem cell therapy
-
Longeveron (LGVN) Misses Q3 EPS by 3c
-
Lilly (LLY), Acumen Pharmaceuticals (ABOS), Others Trade Higher in Sympathy with Biogen (BIIB) Following Alzheimer's Disease Data
-
Longeveron (LGVN) Misses Q2 EPS by 4c
-
Longeveron (LGVN) Announces CEO Resignation, Appoints K. Chris Min as CEO
-
Longeveron (LGVN) Enters Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial
-
Longeveron (LGVN) Files $50M Mixed Securities Shelf
-
Longeveron (LGVN) Files $50M Mixed Shelf
-
Longeveron (LGVN) Appoints Chris Min as Chief Medical Officer
-
Longeveron (LGVN) Extends Yesterday's Gain, Up Another 12%
-
Longeveron (LGVN) Extends Gain, Up 105%
-
Longeveron (LGVN) Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association
-
Maxim Group Starts Longeveron (LGVN) at Buy
-
Longeveron (LGVN) Reports Q4 Loss of $0.20/sh
-
Longeveron (LGVN) Appoints Todd Girolamo to Its Board
-
Longeveron (LGVN) Reports Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
-
Longeveron (LGVN) Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease
-
Longeveron (LGVN) Announces 2.39M Share Offering by Selling Stockholders
Back to LGVN Stock Lookup
